Adaptive Biotechnologies Corp Stock Analysis

Adaptive Stock Analysis Notes

About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adaptive Biotechnologies recorded a loss per share of 1.56. The entity had not issued any dividends in recent years. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 858 people. For more info on Adaptive Biotechnologies Corp please contact Chad MBA at 206 659 0067 or go to https://www.adaptivebiotech.com.

Adaptive Biotechnologies Investment Alerts

Adaptive Biotechnologies Upcoming and Recent Events

Adaptive Largest EPS Surprises

View All Earnings Estimates

Adaptive Stock Institutional Investors

Note, although Adaptive Biotechnologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adaptive Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 364.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adaptive Biotechnologies's market, we take the total number of its shares issued and multiply it by Adaptive Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Adaptive Profitablity

The company has Profit Margin (PM) of (1.32) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.0) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.0.

Management Efficiency

Adaptive Biotechnologies has return on total asset (ROA) of (0.166) % which means that it has lost $0.166 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5834) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 276.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 84.7 M in 2024.

Technical Drivers

As of the 24th of April, Adaptive Biotechnologies shows the mean deviation of 4.07, and Risk Adjusted Performance of (0.06). Adaptive Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Adaptive Biotechnologies Corp, which can be compared to its peers. Please confirm Adaptive Biotechnologies risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Adaptive Biotechnologies is priced correctly, providing market reflects its regular price of 2.58 per share. Please also double-check Adaptive Biotechnologies Corp jensen alpha, which is currently at (0.77) to validate the company can sustain itself at a future point.

Adaptive Biotechnologies Price Movement Analysis

Adaptive Biotechnologies Insider Trading Activities

Adaptive Biotechnologies Predictive Daily Indicators

Adaptive Biotechnologies Corporate Filings

Adaptive Biotechnologies Forecast Models

Adaptive Biotechnologies' time-series forecasting models are one of many Adaptive Biotechnologies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adaptive Biotechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adaptive Biotechnologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adaptive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Adaptive Biotechnologies. By using and applying Adaptive Stock analysis, traders can create a robust methodology for identifying Adaptive entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adaptive analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adaptive analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Adaptive Biotechnologies Corp stock analysis indicators help investors evaluate how Adaptive Biotechnologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adaptive Biotechnologies shares will generate the highest return on investment. By understating and applying Adaptive Biotechnologies stock analysis, traders can identify Adaptive Biotechnologies position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.